Management of rivaroxaban in relation to bodyweight and body mass index

Therapeutic Advances in Cardiovascular Disease

Volumn 10, Issue 5, 2016, Pages 294-303

  Uprichard, James ^a  

^a ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

atrial fibrillation; bodyweight; oral anticoagulant; rivaroxaban; venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RIVAROXABAN; TICLOPIDINE; WARFARIN; BLOOD CLOTTING FACTOR 10A INHIBITOR;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; ATRIAL FIBRILLATION; BLEEDING; BODY MASS; BODY WEIGHT; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG INDICATION; DRUG SAFETY; EMBOLISM; HIP REPLACEMENT; HUMAN; KNEE REPLACEMENT; MAXIMUM PLASMA CONCENTRATION; OBESITY; OUTCOME ASSESSMENT; PATIENT CODING; PRIORITY JOURNAL; REVIEW; THROMBOSIS; VENOUS THROMBOEMBOLISM; PHASE 3 CLINICAL TRIAL (TOPIC);

BODY MASS INDEX; BODY WEIGHT; CLINICAL TRIALS, PHASE III AS TOPIC; FACTOR XA INHIBITORS; HUMANS; RIVAROXABAN;

EID: 84984694270     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944716643645     Document Type: Review

References (36)

1. Abed H., Wittert G., (2013) Obesity and atrial fibrillation. Obes Rev 14: 929-938.
2. Ageno W., Mantovani L., Haas S., Kreutz R., Monje D., Schneider J., et al. (2015) Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematol 3: e12-e21.
3. ® (rivaroxaban) summary of product characteristics: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000944/WC500057108.pdf (. accessed 4 February 2016).
4. Beyer-Westendorf J., Gelbricht V., Forster K., Ebertz F., Kohler C., Werth S., et al. (2014) Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J 35: 1888-1896.
5. Breuer L., Ringwald J., Schwab S., Kohrmann M., (2013) Ischemic stroke in an obese patient receiving dabigatran. N Engl J Med 368: 2440-2442.
6. Centers for Disease Control and Prevention (2015) About BMI for adults: http://www.cdc.gov/healthyweight/assessing/bmi/adult-bmi/ (. accessed 18 February 2016).
7. Delluc A., Mottier D., Le Gal G., Oger E., Lacut K., (2009) Underweight is associated with a reduced risk of venous thromboembolism. Results from the EDITH case-control study. J Thromb Haemost 7: 728-729.
8. Eriksson B., Borris L., Friedman R., Haas S., Huisman M., Kakkar A., et al. (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358: 2765-2775.
9. Friedman R., Hess S., Berkowitz S., Homering M., (2013) Complication rates after hip or knee arthroplasty in morbidly obese patients. Clin Orthop Relat Res 471: 3358-3366.
10. Garcia D., Baglin T., Weitz J., Samama M., (2012) Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141: e24S-e43S.
11. Hainer V., Aldhoon-Hainerova I., (2013) Obesity paradox does exist. Diabetes Care 36 (Suppl. 2): S276-S281.
12. ® (rivaroxaban) prescribing information: http://www.xareltohcp.com/sites/default/files/pdf/xarelto-0.pdf (. accessed 4 February 2016).
13. Kakkar A., Brenner B., Dahl O., Eriksson B., Mouret P., Muntz J., et al. (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372: 31-39.
14. Kakkar A., Mueller I., Bassand J., Fitzmaurice D., Goldhaber S., Goto S., et al. (2012) International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J 163: 13-19.
15. Kreutz R., (2014) Pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor. Curr Clin Pharmacol 9: 75-83.
16. Kubitza D., Becka M., Roth A., Mueck W., (2008) Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 24: 2757-2765.
17. Kubitza D., Becka M., Wensing G., Voith B., Zuehlsdorf M., (2005) Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61: 873-880.
18. Kubitza D., Becka M., Zuehlsdorf M., Mueck W., (2007) Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 47: 218-226.
19. Lassen M., Ageno W., Borris L., Lieberman J., Rosencher N., Bandel T., et al. (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358: 2776-2786.
20. Lavie C., McAuley P., Church T., Milani R., Blair S., (2014) Obesity and cardiovascular diseases: implications regarding fitness, fatness, and severity in the obesity paradox. J Am Coll Cardiol 63: 1345-1354.
21. Mahlmaan A., Gehrisch S., Beyer-Westendorf J., (2013) Pharmacokinetics of rivaroxaban after bariatric surgery: a case report. J Thromb Thrombolysis 364: 533-535.
22. Mega J., Braunwald E., Wiviott S., Bassand J., Bhatt D., Bode C., et al. (2012) Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366: 9-19.
23. Nutescu E., Chuatrisorn I., Hellenbart E., (2011) Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 31: 326-343.
24. Patel M., Mahaffey K., Garg J., Pan G., Singer D., Hacke W., et al. (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365: 883-891.
25. Piccini J., Fraulo E., Ansell J., Fonarow G., Gersh B., Go A., et al. (2011) Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J 162: 606-612.
26. Prins M., Lensing A., Bauersachs R., van Bellen B., Bounameaux H., Brighton T., et al. (2013) Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 11: 21.
27. Rafferty J., Prom R., Kujawski S., (2013) Acute pulmonary emboli in a patient on long-term dabigatran therapy. Ann Pharmacother 47: e20.
28. Safouris A., Demulder A., Triantafyllou N., Tsivgoulis G., (2014) Rivaroxaban presents a better pharmacokinetic profile than dabigatran in an obese non-diabetic stroke patient. J Neurol Sci 346: 366-367.
29. Stein P., Beemath A., Olson R., (2005) Obesity as a risk factor in venous thromboembolism. Am J Med 118: 978-980.
30. Suastika K., Dwipayana P., Saraswati M., Gotera W., Budhiarta A., Sutanegara N., et al. (2012) Underweight is an important risk factor for coronary heart disease in the population of Ceningan Island, Bali. Diab Vasc Dis Res 9: 75-77.
31. The EINSTEIN Investigators (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363: 2499-2510.
32. The EINSTEIN-PE Investigators (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366: 1287-1297.
33. Turpie A., Lassen M., Davidson B., Bauer K., Gent M., Kwong L., et al. (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373: 1673-1680.
34. Turpie A., Lassen M., Eriksson B., Gent M., Berkowitz S., Misselwitz F., et al. (2011) Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 105: 444-453.
35. Weinz C., Buetehorn U., Daehler H., Kohlsdorfer C., Pleiss U., Sandmann S., et al. (2005) Pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-in rats and dogs. Xenobiotica 35: 891-910.
36. Wendelboe A., Hegmann K., Biggs J., Cox C., Portmann A., Gildea J., et al. (2003) Relationships between body mass indices and surgical replacements of knee and hip joints. Am J Prev Med 25: 290-295.